Appendix 4E and Preliminary Financial Report

 

CLINUVEL PHARMACEUTICALS LTD (CLINUVEL), a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4E and Preliminary Financial Report for the year ending 30 June 2019.

Download PDF

We use cookies to give you the best experience.